{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:12:50Z","timestamp":1793819570818,"version":"4.6.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Canada Research Chair for Artificial Pancreas Systems."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41591-024-03463-z","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T05:02:29Z","timestamp":1736485349000},"page":"1239-1245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2389-9066","authenticated-orcid":false,"given":"Melissa-Rosina","family":"Pasqua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Tsoukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Kobayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wedyan","family":"Aboznadah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-2496","authenticated-orcid":false,"given":"Adnan","family":"Jafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6700-0385","authenticated-orcid":false,"given":"Ahmad","family":"Haidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"3463_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1210\/endrev\/bnac022","volume":"44","author":"M Phillip","year":"2023","unstructured":"Phillip, M. et al. Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. Endocr. Rev. 44, 254\u2013280 (2023).","journal-title":"Endocr. Rev."},{"key":"3463_CR2","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"DM Nathan","year":"1993","unstructured":"Nathan, D. M. et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977\u2013986 (1993).","journal-title":"N. Engl. J. Med."},{"key":"3463_CR3","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","volume":"353","author":"DM Nathan","year":"2005","unstructured":"Nathan, D. M. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353, 2643\u20132653 (2005).","journal-title":"N. Engl. J. Med."},{"key":"3463_CR4","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1016\/j.jcjd.2017.10.012","volume":"42","author":"A McGibbon","year":"2018","unstructured":"McGibbon, A., Adams, L., Ingersoll, K., Kader, T. & Tugwell, B. Glycemic management in adults with type 1. Can. J. Diabetes 42, S80\u2013S87 (2018).","journal-title":"Can. J. Diabetes"},{"key":"3463_CR5","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.2337\/dc20-S006","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association 6. Glycemic targets: Standards of Medical Care in Diabetes-2020. Diabetes Care 43, S66\u2013S76 (2020).","journal-title":"Diabetes Care"},{"key":"3463_CR6","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2337\/dc18-2316","volume":"42","author":"T Danne","year":"2019","unstructured":"Danne, T. et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 42, 1147\u20131154 (2019).","journal-title":"Diabetes Care"},{"key":"3463_CR7","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","volume":"381","author":"SA Brown","year":"2019","unstructured":"Brown, S. A. et al. Six month randomized, multicenter trial of closed-loop control in type 1 diabetes. N. Engl. J. Med. 381, 1707\u20131717 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3463_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S0140-6736(20)32514-9","volume":"397","author":"RM Bergenstal","year":"2021","unstructured":"Bergenstal, R. M. et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet 397, 208\u2013219 (2021).","journal-title":"Lancet"},{"key":"3463_CR9","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.2337\/dc21-0172","volume":"44","author":"SA Brown","year":"2021","unstructured":"Brown, S. A. et al. Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care 44, 1630\u20131640 (2021).","journal-title":"Diabetes Care"},{"key":"3463_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/dom.13052","volume":"20","author":"V Gingras","year":"2018","unstructured":"Gingras, V., Taleb, N., Roy-Fleming, A., Legault, L. & Rabasa-Lhoret, R. The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes. Diabetes Obes. Metab. 20, 245\u2013256 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"3463_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1089\/dia.2021.0568","volume":"24","author":"SA Weinzimer","year":"2022","unstructured":"Weinzimer, S. A. et al. A comparison of postprandial glucose control in the Medtronic advanced hybrid closed-loop system versus 670G. Diabetes Technol. Ther. 24, 573\u2013582 (2022).","journal-title":"Diabetes Technol. Ther."},{"key":"3463_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00508-018-1434-9","volume":"131","author":"P Fellinger","year":"2019","unstructured":"Fellinger, P. et al. Overweight and obesity in type 1 diabetes equal those of the general population. Wien. Klin. Wochenschr. 131, 55\u201360 (2019).","journal-title":"Wien. Klin. Wochenschr."},{"key":"3463_CR13","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1016\/j.orcp.2013.03.007","volume":"8","author":"SA Price","year":"2014","unstructured":"Price, S. A., Gorelik, A., Fourlanos, S., Colman, P. G. & Wentworth, J. M. Obesity is associated with retinopathy and macrovascular disease in type 1 diabetes. Obes. Res. Clin. Pract. 8, e178\u2013e182 (2014).","journal-title":"Obes. Res. Clin. Pract."},{"key":"3463_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40608-018-0193-5","volume":"5","author":"EO Melin","year":"2018","unstructured":"Melin, E. O., Thulesius, H. O., Hillman, M., Landin-Olsson, M. & Thunander, M. Abdominal obesity in type 1 diabetes associated with gender, cardiovascular risk factors and complications, and difficulties achieving treatment targets: a cross sectional study at a secondary care diabetes clinic. BMC Obes. 5, 15 (2018).","journal-title":"BMC Obes."},{"key":"3463_CR15","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/archinternmed.2009.193","volume":"169","author":"DM Nathan","year":"2009","unstructured":"Nathan, D. M. et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years\u2019 duration: the diabetes control and complications trial\/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983\u20132005). Arch. Intern. Med. 169, 1307\u20131316 (2009).","journal-title":"Arch. Intern. Med."},{"key":"3463_CR16","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834\u20131844 (2016).","journal-title":"N. Engl. J. Med."},{"key":"3463_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989\u20131002 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3463_CR18","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3463_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1089\/dia.2023.0490","volume":"26","author":"SK Garg","year":"2024","unstructured":"Garg, S. K. et al. Efficacy of semaglutide in overweight and obese patients with type 1 diabetes. Diabetes Technol. Ther. 26, 184\u2013189 (2024).","journal-title":"Diabetes Technol. Ther."},{"key":"3463_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/endocrines4010008","volume":"4","author":"D Mohandas","year":"2023","unstructured":"Mohandas, D., Calma, J., Gao, C. & Basina, M. Evaluating the efficacy and safety of long-acting GLP-1 receptor agonists in T1DM patients. Endocrines 4, 93\u2013101 (2023).","journal-title":"Endocrines"},{"key":"3463_CR21","first-page":"1","volume":"9","author":"A Weisman","year":"2024","unstructured":"Weisman, A., Booth, G. L. & Everett, K. Recent improvements in attainment of the hemoglobin A1c target of \u2264 7. 0 % among adults with type 1 diabetes in Ontario. Diabetes Technol. Ther. 9, 1\u201327 (2024).","journal-title":"Diabetes Technol. Ther."},{"key":"3463_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.jcjd.2022.05.010","volume":"46","author":"A-S Brazeau","year":"2022","unstructured":"Brazeau, A.-S. et al. Type 1 diabetes population surveillance through the BETTER Patient-Engagement Registry: development and baseline characteristics. Can. J. Diabetes 46, 813\u2013821 (2022).","journal-title":"Can. J. Diabetes"},{"key":"3463_CR23","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.2337\/dc16-0691","volume":"39","author":"C Mathieu","year":"2016","unstructured":"Mathieu, C. et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care 39, 1702\u20131710 (2016).","journal-title":"Diabetes Care"},{"key":"3463_CR24","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2337\/dc16-0690","volume":"39","author":"B Ahr\u00e9n","year":"2016","unstructured":"Ahr\u00e9n, B. et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care 39, 1693\u20131701 (2016).","journal-title":"Diabetes Care"},{"key":"3463_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/dom.13896","volume":"22","author":"VR Aroda","year":"2020","unstructured":"Aroda, V. R. et al. Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: a patient-level, pooled analysis of the SUSTAIN 1\u20135 trials. Diabetes Obes. Metab. 22, 303\u2013314 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"3463_CR26","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s00125-017-4289-0","volume":"60","author":"C Kapitza","year":"2017","unstructured":"Kapitza, C., Dahl, K., Jacobsen, J. B., Axelsen, M. B. & Flint, A. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia 60, 1390\u20131399 (2017).","journal-title":"Diabetologia"},{"key":"3463_CR27","doi-asserted-by":"publisher","first-page":"S258","DOI":"10.2337\/dc11-s230","volume":"34","author":"AJ Garber","year":"2011","unstructured":"Garber, A. J. Incretin effects on \u03b2-cell function, replication, and mass: the human perspective. Diabetes Care 34, S258\u2013S263 (2011).","journal-title":"Diabetes Care"},{"key":"3463_CR28","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1111\/dom.14532","volume":"23","author":"TF Dejgaard","year":"2021","unstructured":"Dejgaard, T. F. et al. Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials. Diabetes Obes. Metab. 23, 2752\u20132762 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"3463_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S2213-8587(21)00019-X","volume":"9","author":"M von Herrath","year":"2021","unstructured":"von Herrath, M. et al. Anti-interleukin-21 antibody and liraglutide for the preservation of \u03b2-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 9, 212\u2013224 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3463_CR30","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.2337\/dc20-1560","volume":"43","author":"V Lehmann","year":"2020","unstructured":"Lehmann, V. et al. Lower daily carbohydrate intake is associated with improved glycemic control in adults with type 1 diabetes using a hybrid closed-loop system. Diabetes Care 43, 3102\u20133105 (2020).","journal-title":"Diabetes Care"},{"key":"3463_CR31","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2018-02685","volume":"104","author":"VA Fonseca","year":"2019","unstructured":"Fonseca, V. A. et al. Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide. J. Clin. Endocrinol. Metab. 104, 4078\u20134086 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3463_CR32","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s13300-020-00796-z","volume":"11","author":"M Capehorn","year":"2020","unstructured":"Capehorn, M., Ghani, Y., Hindsberger, C., Johansen, P. & J\u00f3dar, E. Once-weekly semaglutide reduces HbA1c and body weight in patients with type 2 diabetes regardless of background common OAD: a subgroup analysis from SUSTAIN 2\u20134 and 10. Diabetes Ther. 11, 1061\u20131075 (2020).","journal-title":"Diabetes Ther."},{"key":"3463_CR33","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/dom.13120","volume":"20","author":"JB Hjerpsted","year":"2018","unstructured":"Hjerpsted, J. B. et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes. Metab. 20, 610\u2013619 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"3463_CR34","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1210\/clinem\/dgad326","volume":"108","author":"A Ingersen","year":"2023","unstructured":"Ingersen, A. et al. Effects of aerobic training and semaglutide treatment on pancreatic \u03b2-cell secretory function in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 108, 2798\u20132811 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3463_CR35","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.numecd.2021.10.003","volume":"32","author":"Z Yang","year":"2022","unstructured":"Yang, Z. et al. The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system. Nutr. Metab. Cardiovasc. Dis. 32, 504\u2013510 (2022).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"3463_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/pdi.1220","volume":"25","author":"U Graham","year":"2008","unstructured":"Graham, U. & Bell, P. M. Euglycaemic diabetic ketoacidosis. Pr. Diabetes Int. 25, 106 (2008).","journal-title":"Pr. Diabetes Int."},{"key":"3463_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11606-008-0829-0","volume":"24","author":"F Joseph","year":"2009","unstructured":"Joseph, F., Anderson, L., Goenka, N. & Vora, J. Starvation-induced true diabetic euglycemic ketoacidosis in severe depression. J. Gen. Intern. Med. 24, 129\u2013131 (2009).","journal-title":"J. Gen. Intern. Med."},{"key":"3463_CR38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.aace.2023.04.010","volume":"9","author":"PP Sharma","year":"2023","unstructured":"Sharma, P. P., Ramirez-Berlioz, A. M. & Weisz, A. D. Diabetic ketoacidosis in a patient with type I diabetes treated with a closed-loop sensor-augmented insulin infusion system. AACE Clin. Case Rep. 9, 116\u2013121 (2023).","journal-title":"AACE Clin. Case Rep."},{"key":"3463_CR39","doi-asserted-by":"publisher","first-page":"232470962312063","DOI":"10.1177\/23247096231206333","volume":"11","author":"C Widhalm","year":"2023","unstructured":"Widhalm, C. & Pulido, V. Euglycemic diabetic keto acidosis in a type 1 diabetic patient after glucose like peptide-1 administration: a case presentation. J. Investig. Med. High Impact Case Rep. 11, 23247096231206333 (2023).","journal-title":"J. Investig. Med. High Impact Case Rep."},{"key":"3463_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","volume":"11","author":"T Battelino","year":"2023","unstructured":"Battelino, T. et al. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol. 11, 42\u201357 (2023).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3463_CR41","doi-asserted-by":"publisher","first-page":"211s","DOI":"10.1002\/j.1550-8528.1995.tb00466.x","volume":"3","author":"G Blackburn","year":"1995","unstructured":"Blackburn, G. Effect of degree of weight loss on health benefits. Obes. Res. 3, 211s\u2013216s (1995).","journal-title":"Obes. Res."},{"key":"3463_CR42","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1089\/dia.2017.0455","volume":"20","author":"TD Riddlesworth","year":"2018","unstructured":"Riddlesworth, T. D. et al. Optimal sampling duration for continuous glucose monitoring to determine long-term glycemic control. Diabetes Technol. Ther. 20, 314\u2013316 (2018).","journal-title":"Diabetes Technol. Ther."},{"key":"3463_CR43","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.2337\/dc19-2041","volume":"43","author":"L Leelarathna","year":"2020","unstructured":"Leelarathna, L. et al. Duration of hybrid closed-loop insulin therapy to achieve representative glycemic outcomes in adults with type 1 diabetes. Diabetes Care 43, e38\u2013e39 (2020).","journal-title":"Diabetes Care"},{"key":"3463_CR44","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2337\/dc22-0490","volume":"46","author":"M-R Pasqua","year":"2023","unstructured":"Pasqua, M.-R., Jafar, A., Kobayati, A., Tsoukas, M. & Haidar, A. Low-dose empagliflozin as adjunct to hybrid closed-loop insulin therapy in adults with suboptimally controlled type 1 diabetes: a randomized crossover controlled trial. Diabetes Care 46, 165\u2013172 (2023).","journal-title":"Diabetes Care"},{"key":"3463_CR45","unstructured":"Randomisation and Online Databases for Clinical Trials (Sealed Envelope Ltd, 2001); https:\/\/www.sealedenvelope.com\/"},{"key":"3463_CR46","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2337\/dc19-1922","volume":"43","author":"A Haidar","year":"2020","unstructured":"Haidar, A. et al. A novel dual-hormone insulin-and-pramlintide artificial pancreas for type 1 diabetes: a randomized controlled crossover trial. Diabetes Care 43, 597\u2013606 (2020).","journal-title":"Diabetes Care"},{"key":"3463_CR47","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2213-8587(15)00141-2","volume":"3","author":"A Haidar","year":"2015","unstructured":"Haidar, A. et al. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 3, 595\u2013604 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3463_CR48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2213-8587(14)70226-8","volume":"3","author":"A Haidar","year":"2015","unstructured":"Haidar, A. et al. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol. 3, 17\u201326 (2015).","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03463-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03463-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03463-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T14:02:06Z","timestamp":1744812126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03463-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3463"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03463-z","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.-R.P. has received speaker honoraria from Medtronic Diabetes Canada and Abbott Diabetes Care. M.A.T. has received speaker honoraria from AstraZeneca, Bausch Health, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk and Sanofi. A.H. has acted as a consultant for Eli Lilly and has received drugs, supplies, equipment and other in-kind support from Tandem, Adocia, Dexcom, Eli Lilly and Ypsomed. A.K., W.A. and A.J. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}